JP2014518883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518883A5 JP2014518883A5 JP2014512833A JP2014512833A JP2014518883A5 JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5 JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5
- Authority
- JP
- Japan
- Prior art keywords
- tl1a
- monoclonal antibody
- clone
- agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 12
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 102000043656 human TNFSF15 Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488671P | 2011-05-20 | 2011-05-20 | |
| US61/488,671 | 2011-05-20 | ||
| PCT/US2012/028926 WO2012161856A1 (en) | 2011-05-20 | 2012-03-13 | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518883A JP2014518883A (ja) | 2014-08-07 |
| JP2014518883A5 true JP2014518883A5 (cg-RX-API-DMAC7.html) | 2015-03-19 |
Family
ID=47217582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512833A Withdrawn JP2014518883A (ja) | 2011-05-20 | 2012-03-13 | Ｔ細胞媒介疾病の病態を改善させるためのｔｌ１ａ−ｄｒ３相互作用の遮断及びその抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9068003B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2709664A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014518883A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140104344A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012259312A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2836898A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013013329A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012161856A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2428321T3 (es) * | 2003-08-20 | 2013-11-07 | University Of Miami | Composiciones y métodos para tratar la enfermedad del pulmón inflamado |
| CA2621083C (en) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| SG178125A1 (en) | 2009-08-03 | 2012-03-29 | Univ Miami | Method for in vivo expansion of t regulatory cells |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| JP2014531210A (ja) | 2011-09-30 | 2014-11-27 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | ＴＬ１ａに対する抗体およびその使用 |
| JP2016503818A (ja) * | 2013-01-02 | 2016-02-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｌ１ａと結合する抗体およびその使用 |
| WO2014110258A1 (en) | 2013-01-09 | 2014-07-17 | Podack Eckhard R | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
| WO2014160883A1 (en) | 2013-03-27 | 2014-10-02 | Cedars-Sinai Medical Center | Treating fibrosis and inflammation by inhibiting tl1a |
| US20160096885A1 (en) * | 2013-05-17 | 2016-04-07 | Cedars-Sinal Medical Center | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis |
| EP3498867B1 (en) * | 2013-05-17 | 2021-09-29 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
| US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| AU2014317991A1 (en) * | 2013-09-06 | 2016-03-10 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-TL1A therapy |
| SG11201602671WA (en) * | 2013-11-13 | 2016-05-30 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
| CA2947255A1 (en) * | 2014-04-28 | 2015-11-05 | The National Institute for Biotechnology in the Negev Ltd. | Variants of dr3 and use thereof |
| EP3337465B1 (en) | 2015-08-21 | 2021-11-24 | The Children's Hospital of Philadelphia | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US20180319889A1 (en) * | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| EP3458466B1 (en) | 2016-05-20 | 2024-08-07 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
| US10322174B2 (en) * | 2016-10-26 | 2019-06-18 | Cedars-Sinai Medical Center | Neutralizing anti-TL1A monoclonal antibodies |
| EP3784699A4 (en) | 2018-04-25 | 2022-04-13 | Prometheus Biosciences, Inc. | OPTIMIZED ANTI-TL1A ANTIBODIES |
| WO2020113116A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| BR112022007720A2 (pt) | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
| WO2021102433A1 (en) * | 2019-11-22 | 2021-05-27 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
| EP4501966A4 (en) * | 2022-06-17 | 2025-10-22 | Selecxine Inc | ANTIBODY SPECIFICALLY BINDING TO HUMAN DR3 AND ITS USE |
| AU2024273758A1 (en) | 2023-05-17 | 2025-12-04 | Genentech, Inc. | Anti-tl1a antibody therapeutic methods |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
| WO2025076081A1 (en) | 2023-10-03 | 2025-04-10 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE152169T1 (de) | 1988-02-05 | 1997-05-15 | Whitehead Biomedical Inst | Modifizierte hepatozyten und deren anwendung |
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| AU669367B2 (en) | 1992-04-28 | 1996-06-06 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| JP2000501284A (ja) | 1995-11-14 | 2000-02-08 | ビムラックス ホールディングズ，リミテッド | Ｒｎａ切断活性を有するキメラオリゴマー |
| KR0161881B1 (ko) | 1995-12-05 | 1999-02-01 | 문정환 | 메모리의 데이타 읽기회로 |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
| AU7976198A (en) | 1997-06-19 | 1999-01-04 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes with extended cleavage rule |
| CA2399388A1 (en) | 2000-02-11 | 2001-08-16 | Michael J. Lenardo | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
| ES2428321T3 (es) * | 2003-08-20 | 2013-11-07 | University Of Miami | Composiciones y métodos para tratar la enfermedad del pulmón inflamado |
| WO2006127900A2 (en) * | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| CA2621083C (en) * | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| EP2500362A3 (en) * | 2007-11-13 | 2012-10-24 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against TL1A |
-
2012
- 2012-03-13 WO PCT/US2012/028926 patent/WO2012161856A1/en not_active Ceased
- 2012-03-13 CA CA2836898A patent/CA2836898A1/en not_active Abandoned
- 2012-03-13 JP JP2014512833A patent/JP2014518883A/ja not_active Withdrawn
- 2012-03-13 MX MX2013013329A patent/MX2013013329A/es not_active Application Discontinuation
- 2012-03-13 AU AU2012259312A patent/AU2012259312A1/en not_active Abandoned
- 2012-03-13 US US13/419,203 patent/US9068003B2/en active Active
- 2012-03-13 EP EP12790157.7A patent/EP2709664A4/en not_active Withdrawn
- 2012-03-13 KR KR1020137033718A patent/KR20140104344A/ko not_active Withdrawn